Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

INTRODUCTION: Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, ex...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Open
Päätekijät: Johansen, Nicklas Järvelä, Dejgaard, Thomas Fremming, Lund, Asger, Vilsbøll, Tina, Andersen, Henrik Ullits, Knop, Filip Krag
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2018
Aiheet:
Diabetes and Endocrinology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6042609/
https://ncbi.nlm.nih.gov/pubmed/29950475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-021861
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia